News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-05-02-2017
Volume12
Issue 5

Cobra Biologics Expands Gene Therapy Manufacturing Operations

Cobra will increase capacity in response to customer demand for DNA and viral vector production.

Cobra Biologics, an international contract development and manufacturing organization for biologics and pharmaceuticals, will expand operations at its sites in the United Kingdom and Sweden, the company announced on April 18, 2017. Over the next two years Cobra will invest up to £15 million ($19 million) on a phased expansion plan, supporting the company’s R&D expertise in developing rapid and cost-effective viral vector and DNA plasmid production platforms. The initial phase will be in the UK and will extend the company’s viral vector Phase III and commercial manufacturing capabilities to support more customers to rapidly advance their products through clinical trials to in-market supply. The second phase, in Sweden, will double capacity for high quality (HQ) DNA plasmid production and characterization, essential for supporting early clinical phase adeno-associated virus (AAV) and lentivirus manufacture being used by pioneering CAR T-cell therapy companies targeting acute lymphoblastic leukemia and chronic lymphocytic leukemia. The third phase of investment will see the addition of larger clinical and commercial capabilities for GMP DNA production. In total, it is anticipated these investments will create up to 50 new jobs.

Source: Cobra Biologics

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content